Nonclinical Safety Assessment of Oligonucleotide-Based Therapeutics
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
November 15, 2024
November 15, 2024
98302410-dce1-4d17-92eb-6b05f834b01c
Related Documents
Establishing Impurity Specifications for Antibiotics
Guidance DocumentApril 20, 2026Center for Drug Evaluation and Research
Monoclonal Antibodies: Streamlined Nonclinical Safety Studies: Draft Guidance for Industry
Guidance DocumentDecember 2, 2025Center for Drug Evaluation and Research
Data Integrity for In Vivo Bioavailability and Bioequivalence Studies
Guidance DocumentApril 3, 2024Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust KeyPedia for their regulatory compliance needs.